CALGB/SWOG 80405 — Chemotherapy Plus Cetuximab or Bevacizumab as First-Line Treatment for KRAS Wild-Type Metastatic Colorectal Cancer

Phase 3 · 2017 · Colorectal Cancer

Design

Randomized FOLFOX or FOLFIRI plus either cetuximab or bevacizumab as first-line therapy.

Population

Untreated KRAS wild-type (codons 12/13) metastatic colorectal cancer.

Primary Endpoint

overall survival (OS)

Key Result

OS ~30 mo in both arms with no significant difference; later analyses showed primary tumor sidedness strongly predicts anti-EGFR benefit.

Guideline Impact

Informs first-line biologic selection and left- vs right-sided treatment decisions in mCRC